The company is now hoping for an affirmative answer on its application after an unusually turbulent year dealing with U.S.

Though Alumis still sees a path forward in lupus, the result made its drug the latest TYK2 blocker to struggle in conditions beyond psoriasis and psoriatic arthritis.

What's possible when AI models can learn from additional health data modalities to create a more complete understanding of ...

Wall Street analysts believe that a more cautious approach to manufacturing, study enrollment and side effect management ...

In an interview with Stephen Onikoro, chief operating officer of PharmaForceIQ, he shared that pharma marketers can’t pour ...

Side effects observed in testing have led Novartis to halt development of rap-cel in multiple indications and Bristol Myers ...

At a big meeting for cardiovascular medicines, Cytokinetics and Arrowhead aimed to separate their drugs from competitors ...

The big drugmaker’s latest company acquisition this year is centered around a technology designed to degrade proteins that ...

The clearance and broader-than-expected label for Mimrylo open up a yearly revenue opportunity for Takeda that some analysts ...

Focused on Medicaid, the new pacts now involve more than just large pharmaceutical companies, but still aren’t expected to ...

Results published in NEJM raised questions about the benefits “silencer” medications provide on top of standard therapies for ...

A real-world study suggests Zepbound use could reduce the rates of hospital stays and ER visits. Elsewhere, McKesson sprung for a multibillion-dollar deal and J&J nabbed a noteworthy approval.